Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.68 |
| ▸ | KMT5A | Q9NQR1 | 10/20 | 0.62 |
| ▸ | CCR4 | P51679 | 1/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.57 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3637894 | 0.99 | EHMT2 (0.67) | EHMT2KMT5ACCR4CTNNB1TCF7L2 | |
| SCHEMBL3640926 | 0.89 | EHMT2 (0.67) | EHMT2KMT5AHRH4 | |
| SCHEMBL3779698 | 0.89 | WHR1 (0.67) | EHMT2KMT5ACCR4HRH4EGFR | |
| Hydrochloric Acid SCHEMBL3639996 | 0.88 | WHR1 (0.66) | EHMT2KMT5ACCR4HRH4EGFR | |
| SCHEMBL7259546 | 0.86 | KMT5A (0.59) | EHMT2KMT5ACCR4CTNNB1TCF7L2 | |
| SCHEMBL3643545 | 0.85 | CTNNB1 (0.66) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7259303 | 0.82 | KMT5A (0.55) | KMT5ACCR4CTNNB1TCF7L2 | |
| SCHEMBL25363673 | 0.81 | KMT5A (0.54) | EHMT2KMT5ACCR4 | |
| SCHEMBL3641690 | 0.80 | CTNNB1 (0.76) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3642962 | 0.79 | PDE5A (0.71) | EHMT2KMT5AHRH4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | EHMT2 3769/4885KMT5A 4674/4885CCR4 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.